AKT1 and type 2 diabetes mellitus: In summary, the oral administration of Zn(ASA)2 not only decreases blood glucose levels, but also alleviates type-2 diabetes-induced damage in rat cardiac tissue, in part via the activation of the myocardial AKT signalling pathway.